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Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor
in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & meth-
ods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-
levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-
effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT –
General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3.
The estimated difference in health state utilities for treatment response and progressive disease was both
statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients
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with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated
with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
Lay abstract: This work examined quality of life (QoL) among patients with relapsed/refractory diffuse
large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL
clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy – Lymphoma and Euro-
QoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor
maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events
were not associated with clinically meaningful negative QoL impacts.
Clinical trial registration: NCT02227251 (ClinicalTrials.gov)
First draft submitted: 14 September 2020; Accepted for publication: 3 December 2020; Published
online: 2 February 2021
Keywords: diffuse large B-cell lymphoma • disutility of adverse events • EQ-5D-5L • FACT-Lym • health-related
quality of life • health state utility • health utility • patient-reported outcomes • selinexor
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, fast-growing malignancy of B-lymphocytes [1,2]. DLBCL
is the most common subtype of non-Hodgkin lymphoma (NHL) malignancies and accounted for 25% of NHL
cases in 2016 in the USA [3]. According to the Surveillance, Epidemiology, and End Results Program data from
2012 to 2016, the incidence of DLBCL in the USA was 5.6 per 100,000 per year [4]. Despite high cure rates with
first-line standard of care chemoimmunotherapy regimens, an estimated 30–40% of patients relapse [1,5–10]. In
the second-line setting, fit, transplant-eligible patients may progress to high-dose therapy and autologous stem cell
transplantation (ASCT), leading to long-term remission for some patients. However, for patients who relapse after
salvage therapy, with or without ASCT, outcomes are especially poor, with median overall survival (OS) in cohort
studies ranging from 4.7 to 6.6 months from commencement of salvage therapy [11–17]. While no standard of care
treatment regimen exists in the third-line setting, options include emergent therapies such as chimeric antigen
receptor (CAR) T-cell therapy and polatuzumab vedotin plus rituximab and bendamustine, as well as alternate
chemoimmunotherapy regimens, clinical trials, palliative radiation therapy or best supportive care [5].
Selinexor is an orally bioavailable selective nuclear export inhibitor [18–21]. Selinexor was approved in 2020 for
the treatment of adult patients with relapsed/refractory DLBCL (RR DLBCL), not otherwise specified, after two
prior lines of systemic therapy [22]. Safety and efficacy of selinexor were demonstrated in the single-arm, Phase IIb,
open-label, multicenter SADAL trial in transplant-ineligible patients with RR DLBCL who received two to five
prior systemic therapies (n = 127 in the modified intent-to-treat [mITT] population) [22,23]. The SADAL trial met
the primary end point with an overall response rate of 28% (95% CI: 20.7–37.0; n = 36); complete response (CR)
rate was 12% (n = 15) and partial response (PR) rate was 17% (n = 21) [23]. Median duration of response was
9.3 months (95% CI: 4.8–23.0) for all responders and 23.0 months (95% CI: 10.4–23.0) for patients in CR
at a median follow-up time of 11.1 months [23]. Median OS was 9.1 months (95% CI: 6.6–15.1) at a median
follow-up time of 14.7 months and was not reached for patients in CR. The most common grade 3–4 adverse
events (AEs) were thrombocytopenia (46%), neutropenia (25%), anemia (22%), fatigue (11%), hyponatremia
(8%) and nausea (6%). Serious AEs (SAEs) occurred in 48% of patients, with the most common being pyrexia
(7%), pneumonia (5%), sepsis (5%) and fatigue (4%). Selinexor was well tolerated, with treatment-emergent
AEs managed with supportive care and/or dose modifications.
In addition to clinical efficacy and safety end points, patient-reported health-related quality of life (HRQoL)
was an exploratory end point in SADAL and was assessed using the Functional Assessment of Cancer Therapy –
Lymphoma (FACT-Lym) questionnaire and the EuroQoL five-dimensions five-levels (EQ-5D-5L) instrument [23].
Previous reports have identified that DLBCL has a high humanistic burden and patients experience poor HRQoL
resulting from disease symptoms and AEs related to treatment that interfere with physical, social and role function-
ing [24–27]. Furthermore, HRQoL declines with disease progression, and across increasing lines of therapy [27,28].
Patient-reported outcomes evidence such as HRQoL, along with clinical outcomes and survival benefit, are an
important consideration in treatment decision making and contribute to a better understanding of the potential
value of new therapies [29–35]. Disease-specific assessments such as the FACT-Lym can capture clinically-relevant,
disease-specific symptomatic burden and disease-specific well-being [36–38]. In contrast, generic instruments such
as the EQ-5D-5L can enable estimation of health utility scores, HRQoL relative to full health (i.e., score of 1) or
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death (i.e., score of 0) [39–41]. Health utility scores can be compared across diseases and applied in health economic
analyses to evaluate outcomes such as quality-adjusted life years [39–41].
The objective of this study was to examine HRQoL and health utilities outcomes with single-agent selinexor in
patients with RR DLBCL using patient-reported FACT-Lym and EQ-5D-5L data captured in the SADAL trial.
The analyses used mixed effects models to evaluate longitudinal trends in HRQoL following initiation of selinexor,
including minimal clinically meaningful differences (MCID), and examined the association between HRQoL and
response to treatment. In addition, mixed-effects models were used to estimate health utility based on treatment
response and derive health state utility values and disutilities associated with AEs/SAEs.
Patients & methods
Study design
SADAL was a global, single-arm, open-label, Phase IIb study of single-agent selinexor in patients with RR DL-
BCL [42]. Full study details and patient eligibility criteria have been described elsewhere [23]. Briefly, eligible patients
were ≥18 years of age, with an estimated life expectancy of >3 months at study entry and had received two to
five prior systemic regimens including at least one course of anthracycline-based chemotherapy and at least one
course of anti-CD20 immunotherapy. Patients had pathologically confirmed de novo DLBCL or DLBCL trans-
formed from previously diagnosed indolent lymphoma. Patients were excluded if they had primary mediastinal
B-cell lymphoma, DLBCL with meningeal involvement, or known CNS lymphoma, or were eligible for high-dose
therapy with ASCT. The study protocol was approved by the institutional review board or an independent ethics
committee at each study center. Oral selinexor (60 mg) was administered as a single agent on days 1 and 3 of each
week (bi-weekly [BIW]) until disease progression, death or unacceptable toxicities.
Data collection, patient-reported HRQoL & health utility assessments
Patients self-administered and completed the FACT-Lym (version 4) questionnaire and the EQ-5D-5L instrument.
Data were collected at baseline (screening visit 2), on day 1 of each 28-day treatment cycle beginning at cycle 2, and
at end of treatment (EOT; i.e., time of drug discontinuation). FACT-Lym is an instrument that has been previously
applied to measure HRQoL in patients with B-cell malignancies [43–46], including RR DLBCL [47]. FACT-Lym
combines the general version of the FACT, in other words, FACT – General (FACT-G; 27 items in four primary
domains) with a lymphoma subscale (Lym domain; 15 items) [36,37]. The Lym domain addresses lymphoma-specific
well-being in terms of symptomatic burden and impact of treatments. The FACT-Lym total score (TS; score range:
0–168) is obtained by adding individual subscale scores for physical well-being (7 items), social/family well-being
(7 items), emotional well-being (6 items) and functional well-being domains (7 items) of the FACT-G (score range:
0–108) and the Lym domain (score range: 0–60). The FACT-Lym Trial Outcome Index (TOI) is comprised of
the physical and functional subscales of the FACT-G and the Lym domain (score range: 0–116). Higher scores
for the FACT-G, FACT-Lym TOI, and FACT-Lym TS indicate better HRQoL [36,37]. Assessment completeness
was defined according to the FACT-Lym Scoring Guidelines (version 4), which allows subscales to be calculated if
>50% of items are present, and TSs if >80% of items are present [36,37].
Health utility in SADAL was captured with the EQ-5D-5L instrument. The EQ-5D-5L instrument includes
dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with five response
levels [41,48]. Response for each dimension is coded as a single-digit number where level 1 equates to no problems
and level 5 to extreme problems. Combined, the five dimensions create a five-digit score that corresponds to the
health state. Data were scored using a crosswalk between patient profiles (i.e., five-digit score) and the EQ-5D-5L
index was calculated based on the US standard value set [40]. As a result, data for each of the five dimensions were
required to be assessed as complete for inclusion in the analysis and to enable derivation of a final index value. It
should be noted that patient-reported visual analog scale data were not captured in the SADAL trial.
Statistical analysis
Number of patients & patient characteristics
The HRQoL dataset included patients who received at least one 60-mg dose of selinexor in the mITT population
(n = 127), had complete data from baseline and at least one follow-up visit, and had complete baseline prognostic
variable data. The analysis considered covariates of sex, age, race, ethnicity and Eastern Cooperative Oncology
Group performance status (ECOG PS) for inclusion in the longitudinal models. Patients with missing ECOG PS
at baseline, which was found to be a statistically significant covariate, were omitted from the HRQoL and health
utility analyses. Treatment responders corresponded to patients with objective response (CR or PR) in SADAL
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according to the 2014 Lugano criteria for response assessment of lymphoma by independent central review [42,49].
In analyses stratified by best overall treatment response status, patients who did not have evaluable response were
excluded. For the FACT-Lym dataset, patient visits with <80% of items answered for the TS and <50% for
subscales were excluded from the analysis. Cycles with <20% of the sample were not included in the analysis
(e.g., unscheduled visits) to limit bias which could result from small sample sizes. For the health utility dataset,
cycles after eight were excluded due to having <20% of patients, with data at baseline, remaining on treatment.
Longitudinal regression analysis
Longitudinal models were constructed to evaluate the magnitude of change from baseline for the FACT-G, FACT-
Lym TOI, FACT-Lym TS and EQ-5D-5L health utility for each follow-up cycle. Mixed-effects linear regression
models were constructed allowing for random slope and intercept terms. Categorical time (i.e., cycle) was treated
as a fixed and random effect. Univariate, multivariate and stepwise techniques were tested to identify covariates
that improved fit. Models were adjusted for baseline HRQoL score and relevant baseline patient characteristics that
improved fit (p < 0.10); nonsignificant (p > 0.10) covariates were excluded. Only final adjusted models which
include baseline scores and specified baseline characteristics that improved fit are reported.
Minimal clinically important differences
Estimated differences in scores based on treatment response status were compared against MCID thresholds
obtained from the literature. An MCID represents the minimum clinically meaningful change in patient-reported
HRQoL scores for a validated instrument, and may be interpreted as the minimum level of perceived benefit with
a therapy option by the patient [50,51]. MCIDs were identified through a targeted literature search for previously
validated ranges for the lower and upper thresholds determined through distribution- and anchor-based methods.
MCID ranges were 3–7 for the FACT-G, 5.5–11 for the FACT-Lym TOI and 6.5–11.2 for the FACT-Lym TS [47].
For the EQ-5D-5L, Pickard et al. [52] recommended a threshold of 0.06 for identifying MCID in US-index scores,
while Kvam et al. [53] suggested the threshold range of 0.08–0.1. Based on these two previous validation studies, the
analysis herein considered 0.06 as the lower threshold limit of MCID and 0.1 as the upper limit. The proportions
of patients experiencing HRQoL or health utility improvement, maintenance or decline based on the high and
low MCID limits were calculated for each score at each cycle. Patients having an increase in score that exceeded
the MCID threshold were considered as having clinically meaningful improvement, while those having a decrease
greater than the MCID threshold were considered as having clinically meaningful decline. Patients with change
less than the MCID were considered stable.
Responder analysis
Differential attrition rates were observed between responders and nonresponders which motivated the use of
mixed-effects models rather than pairwise t-tests by cycle visit. The mixed-effect models assumed data are missing-
at-random, which is less robust than an assumption of missing completely at random as in pairwise analysis.
The missing-at-random assumption was tested by examining patterns of missingness in the trial data. Unlike
the longitudinal regression models which treated time as categorical, the responder analysis considered time as a
continuous variable to account for varying EOT visit times. This approach was required to ensure that comparisons
between responders and nonresponders were not confounded by differential discontinuation dates. The mixed-
effects models included a random intercept, time as a fixed and random effect, baseline score and adjusted models
included ECOG PS as a covariate.
The interaction effect of treatment response (i.e., objective response or no response) and time was estimated
to compare the differences in FACT-G, FACT-Lym TOI, FACT-Lym TS and EQ-5D-5L index scores based on
responder status over the course of follow-up. An interaction effect of treatment and time was considered present
based on a significance level of 0.05 for the interaction coefficient. Mean differences in scores were estimated
directly from the mixed effects model at each cycle. In the analysis, a positive estimated mean difference implies that
treatment responders had higher relative HRQoL than nonresponders at that cycle. An interaction term between
responder status and time was introduced in all responder analysis where the interaction was statistically significant
to minimize the risk of bias associated with differential attrition. Estimated differences in scores based on treatment
response status were compared against MCID thresholds obtained from the literature.
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Figure 1. Study flowchart (patient disposition).
†Patient visits were dropped if <80% of items were answered for the total score, if <50% of items were answered for the subscale, if they
were unscheduled visits, or if <20% of the sample answered the questionnaire at that cycle (the whole cycle was dropped in this case).
‡The longitudinal analysis cohort required baseline health-related quality of life data, at minimum one follow-up health-related quality
of life data data and Eastern Cooperative Oncology Group performance status data at baseline.
§The longitudinal analysis cohort required baseline data and at minimum one follow-up EQ-5D-5L assessment.
EQ-5D-5L: EuroQoL five-dimensions five-levels; FACT-G: Functional Assessment of Cancer Therapy – general; FACT-TOI: FACT – Lymphoma
Trial Outcome Index; FACT-Lym: FACT – lymphoma.
Health state utility values & disutility of AEs
The analysis sought to evaluate how utility values differed for patients based on response to selinexor treatment
and disease progression. Three health states of progressive disease, stable disease and response were considered,
which were derived based on best overall response as assessed by an independent central review panel. Each patient
was considered to have stable disease at baseline. At cycle 2, patients were categorized based on the best overall
response. Mixed effects linear regression models were constructed with the EQ-5D-5L index as the outcome. A
random intercept was included and categorical time (i.e., cycle) was treated as a fixed and random effect. Mean
values for each disease state at baseline and EOT were estimated. The coefficients for progression representing the
mean differences between health states were estimated with 95% CIs and p-values.
The disutilities of aggregate and individual grade ≥3 AEs and SAEs with ≥10% prevalence in SADAL were
analyzed. A disutility represents a loss in EQ-5D-5L utility score (i.e., decrease in HRQoL) that is associated with
experiencing an AE/SAE. All models included the baseline EQ-5D-5L index score and coefficients, 95% CIs, and
p-values were reported as adjusted for health states (i.e., disease progression). Due to the small sample sizes and
patient attrition, the change associated with AEs was estimated based on all postbaseline cycles.
Results
Patient characteristics
From the mITT population (n = 127), the QoL dataset included 105 patients for the FACT-G and FACT-Lym
TOI, and 104 patients for the FACT-Lym TS who had completed enough items at baseline and at least one
follow-up treatment cycle (Figure 1). Following exclusion of patients with no baseline ECOG PS data, 101 patients
were retained in the longitudinal analysis cohort for each score. A total of 83 patients with complete FACT-G and
FACT-Lym TS data had an evaluable response, of whom 32 were treatment responders and 51 were nonresponders.
Similarly, 84 patients with complete FACT-Lym TOI had an evaluable response, with 33 treatment responders and
51 nonresponders. In the HRQoL dataset (n = 101), mean age was 66.3 (standard deviation [SD]: 10.4; range:
35–87) and 58% of patients were male (n = 59) (Table 1). The proportions of patients with ECOG PS of 0, 1 and
2 were 48% (n = 48), 45% (n = 46) and 8% (n = 8), respectively.
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Table 1. Baseline characteristics of patients in the health-related quality of life and health utility datasets.
Characteristic HRQoL dataset value Health utility dataset value
N 101 89
Male 59 (58%) 48 (53.9%)
Mean age (SD), years 66.3 (10.4) 66.1 (10.3)
Age group (n, %):
– 18–50 7 (7%) 6 (6.7%)
– 51–64 33 (33%) 29 (32.6%)
– 65–74 36 (36%) 34 (38.2%)
– ≥75 25 (24%) 20 (22.5%)
Race (n, %):
– White 79 (78%) 69 (77.5%)
– Asian 10 (10%) 10 (11.2%)
– Other 6 (6%) 4 (4.5%)
– Missing 6 (6%) 6 (6.7%)
– Ethnicity
– Non-Hispanic or Latino 79 (78%) 71 (79.8%)
– Hispanic or Latino 5 (5%) 5 (5.6%)
– Unknown 4 (4%) 3 (3.4%)
– Not reported 11 (11%) 10 (11.2%)
– Missing 2 (2%) –
ECOG PS:
– 0 48 (48%) 42 (47.2%)
– 1 45 (46%) 41 (46.1%)
– 2 8 (8%) 5 (5.6%)
– Missing 0 1 (1.1%)
ECOG PS: Eastern Cooperative Oncology Group performance status; HRQoL: Health-related quality of life; SD: Standard deviation.
Similarly, from the mITT population of SADAL (n = 127), the health utility dataset included 89 patients with
EQ-5D-5L index score at baseline and at least one follow-up cycle (Figure 1). Among patients in the health utility
dataset, the mean age was 66.1 years (SD = 10.3) and 53.9% of patients were male (n = 48) (Table 1). The
proportions of patients with ECOG PS of 0, 1 and 2 were 47.2% (n = 42), 46.1% (n = 41) and 5.6% (n = 5),
respectively. A total of 75 patients with complete EQ-5D-5L data had an evaluable response, of whom 31 had
objective response and 44 were nonresponders.
It should be noted that baseline characteristics of included patients and excluded patients were largely similar
in the two cohorts. One noteworthy exception was that the proportion of excluded patients with ECOG PS of 2
was higher versus included patients in both the HRQoL (25 vs 8%) and the EQ-5D-5L (27.3 vs 5.6%) cohort.
Furthermore, more men were excluded from the EQ-5D-5L cohort (68.2 vs 53.9%).
HRQoL analyses
Results from the mixed-effects regression analysis for the FACT-G, FACT-Lym TOI and the FACT-Lym TS are
shown in Figure 2A–C. Model coefficients are presented in Supplementary Table 1. Final optimized models were
adjusted for baseline scores and baseline ECOG PS (0, 1 or 2). The number of patients remaining in the HRQoL
dataset declined with each cycle. HRQoL decreased across all three scores between baseline and the final visit with
differences of -6.0 (95% CI: -9.2 to -2.8), -8.6 (95% CI: -13.0 to -4.3) and -9.9 (95% CI: -15.5 to -4.3) for
FACT-G, FACT-Lym TOI and FACT-Lym TS, respectively. Observed decreases from baseline were significant at
early cycles of treatment and at the EOT.
Health utility analyses
Results of the mixed-effects regression analysis are presented in Figure 2D, with model coefficients indicated in
Supplementary Table 2. Patients had a mean of four assessments (range: 2–9). The number of patients remaining in
the health utility dataset declined from baseline to cycle 8. Final optimized models were adjusted for baseline EQ-
5D-5L index scores and baseline ECOG PS (0, 1 or 2), which was identified as a significant covariate (p < 0.01).
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Figure 2. Longitudinal changes in quality of life and health utility. Longitudinal change in health-related quality of life as evaluated by
mixed-effects regression models for (A) Functional Assessment of Cancer Therapy – General, (B) Functional Assessment of Cancer Therapy
– Lymphoma Trial Outcome Index, (C) Functional Assessment of Cancer Therapy – Lymphoma total score and (D) EuroQoL five-dimensions
five-levels index score. Models were adjusted for baseline score and Eastern Cooperative Oncology Group performance status.
EOT: End of treatment; EQ-5D-5L: EuroQoL five-dimensions five-levels; FACT-G: Functional Assessment of Cancer Therapy – general;
FACT-TOI: FACT – Lymphoma Trial Outcome Index; FACT-Lym: FACT – lymphoma.
EQ-5D-5L index scores decreased from baseline at each cycle. Observed decreases were significant in cycles 2–4,
and at the EOT (-0.10 [95% CI: -0.15 to -0.05]; p < 0.001). Majority of patients experienced no clinically
meaningful change in the EQ-5D-5L index score from baseline through to cycle 8 based on the lower and upper
MCID thresholds of 0.06 and 0.1, respectively.
Minimal clinically important differences
The proportions of patients achieving clinically important change in HRQoL according to each score were evaluated
based on MCID thresholds reported in literature. Based on the MCID lower limit, majority of patients experienced
decline in FACT-G (Figure 3A; Supplementary Table 3), FACT-Lym TOI (Figure 3B; Supplementary Table 4) and
FACT-Lym TS (Figure 3C; Supplementary Table 5) during the early cycles of treatment and EOT. Based on the
MCID upper limit, majority of patients experienced no change or improvement in FACT-G, FACT-Lym TOI and
FACT-Lym TS compared with baseline for early cycles but experienced decline at the EOT. For the EQ-5D-5L
index score, the majority of patients experienced no change or improvement from baseline according to the lower
and upper MCID limit (Figure 3D).
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Figure 3. Proportion of patients with decline, no change and improvement in health-related quality of life scores
based on the lower and upper limit of minimal clinically important difference thresholds for (A) Functional
Assessment of Cancer Therapy – General, (B) Functional Assessment of Cancer Therapy – Lymphoma Trial Outcome
Index, (C) Functional Assessment of Cancer Therapy – Lymphoma total score and (D) EuroQoL five-dimensions
five-levels index score.
EOT: End of treatment; EQ-5D-5L: EuroQoL five-dimensions five-levels; FACT-G: Functional Assessment of Cancer
Therapy – general; FACT-TOI: FACT – Lymphoma Trial Outcome Index; FACT-Lym: FACT – lymphoma.
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MD = 7.6MD = 6MD = 4.5MD = 2.9MD = 1.3MD = -0.2
Higher is better
Responders Non-responders
Figure 4. Longitudinal health-related quality of life difference analysis – mean differences in health-related quality of life scores
between objective responders and nonresponders for (A) Functional Assessment of Cancer Therapy – General, (B) Functional Assessment
of Cancer Therapy – Lymphoma Trial Outcome Index, (C) Functional Assessment of Cancer Therapy – Lymphoma total score and (D)
EuroQoL five-dimensions five-levels index score. Models were adjusted based on baseline Eastern Cooperative Oncology Group
performance status. A positive estimated mean difference implies that responders had higher relative health-related quality of life than
nonresponders at that cycle.
EQ-5D-5L: EuroQoL five-dimensions five-levels; FACT-G: Functional Assessment of Cancer Therapy – general; FACT-TOI: FACT – Lymphoma
Trial Outcome Index; FACT-Lym: FACT – lymphoma; MD: Mean difference.
Responder analysis
Model-based estimated mean differences in HRQoL scores between treatment responders and nonresponders are
presented in Figure 4A–C for the three scores at baseline and follow-up cycles. Predicted HRQoL means of the
responder analysis are presented in Supplementary Table 6 for the FACT-G, Supplementary Table 7 for the FACT-
Lym TOI and Supplementary Table 8 for the FACT-Lym TS. Results of the responder analysis showed a significant
interaction between responder status and time for the FACT-G (p = 0.05) and FACT-Lym TS (p = 0.05), while
the interaction was not significant for FACT-Lym TOI (p = 0.10). While the interaction was not significant for
the FACT-Lym TOI, the difference in mean scores was similar to the FACT-G over six cycles; therefore, the lack of
observed significance could be caused by higher variability in patient responses. At baseline, scores for the FACT
G, FACT-Lym TOI and FACT-Lym TS were similar for responders and nonresponders, indicating no significant
differences in HRQoL. However, responders had higher scores by cycle 2 for the FACT-G, FACT-Lym TOI and
FACT-Lym TS. The differences in scores between responders and nonresponders became significant (p ≤ 0.05) by
cycle 3 for the FACT-G and the FACT-Lym TS (Figure 4), denoting higher HRQoL among responders. Observed
differences increased with each cycle, indicating that treatment responders maintained a higher HRQoL over a
longer period of time while nonresponders declined rapidly. Nonresponders experienced decline in scores from
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Table 2. Estimated EuroQoL five-dimensions five-levels health state utility values.
Health status Baseline estimated mean (95% CI) End of treatment estimated mean (95% CI)
Progressive disease 0.731 (0.668–0.793) 0.669 (0.619–0.719)
Stable disease 0.783 (0.756–0.809) 0.721 (0.658–0.784)
Response 0.801 (0.741–0.861) 0.739 (0.689–0.790)
Pairwise comparisons Difference (95% CI) p-value
Progressive vs stable disease -0.052 (0.004 to -0.109) 0.073
Response vs progressive disease 0.07 (0.029–0.111) 0.001
Response vs stable disease 0.018 (-0.035–0.072) 0.507
baseline that exceeded the lower MCID threshold by cycle 3 for the FACT-G (≥3, Supplementary Table 6), and
by cycle 4 for the FACT-TOI (≥5.5, Supplementary Table 7) and the FACT-Lym TS (≥6.5, Supplementary Table
8). Furthermore, the observed declines exceeded the upper MCID thresholds by cycle 5 for the FACT-G (≥7) and
FACT-Lym TS (≥12.5) and cycle 6 for the FACT-TOI (≥5.5). In responders, changes in scores from baseline did
not exceed the lower or upper limit of the MCIDs for any score at any follow-up cycle.
Likewise, model-based estimated mean differences in EQ-5D-5L index scores between treatment responders
(n = 31) and nonresponders (n = 44) at baseline and follow-up cycles are presented in Figure 4D. Predicted
EQ-5D-5L means of the responder analysis are presented in Supplementary Table 9. The mixed-effects models,
adjusted for baseline ECOG PS, revealed a significant interaction between time and responder status (p = 0.002).
Baseline EQ-5D-5L index scores were similar for responders and nonresponders suggesting a similar health utility.
By cycle 2, treatment responders had higher estimated mean scores. This difference became significant by cycle
3 (mean difference: 0.075 [95% CI: 0.023–0.126]; p < 0.001), and was maintained through to cycle 7 (mean
difference: 0.249 [95% CI: 0.095–0.402]; p < 0.001). Treatment responders did not experience a decline in scores
that exceeded the lower or upper threshold of MCIDs at any cycle. Nonresponders experienced decline in scores
from baseline, where the lower threshold limit of MCID was exceeded by cycle 3, and upper threshold limit of
MCID was exceeded by cycle 4.
Health state utility
Estimated mean health state utility values at the EOT were 0.669 (95% CI: 0.619–0.719) for progressive disease,
0.721 (95% CI: 0.658–0.784) for stable disease and 0.739 (95% CI: 0.689–0.790) for treatment response (Table 2).
Pairwise analysis identified that patients with stable disease had numerically superior health state utility compared
with patients with progressive disease, however the difference was not significant (p = 0.073). Responders had
significantly higher health state utility compared with patients with progressive disease (p = 0.001) but not stable
disease (p = 0.507). The estimated mean difference between health states of treatment response and progressive
disease exceeded the lower threshold of the MCID of 0.06 (mean difference: 0.07 [95% CI: 0.029–0.111]).
Disutility analysis
Mixed-effects regression models were adjusted for disease progression to estimate disutilities associated with AEs and
SAEs with >10% incidence in SADAL (Table 3). In the EQ-5D-5L analysis cohort, 88% of patients experienced
at least one grade ≥3 AE, with 47% of patients experiencing at least one SAE. Having at least one grade ≥3 AE
resulted in a significant reduction in the EQ-5D-5L index, with a mean difference of -0.036 (95% CI: -0.067
to -0.006; p = 0.02). Individual AEs were generally negatively associated with the EQ-5D-5L index score, and
significant negative associations were observed for any grade ≥3 AE and metabolism and nutrition disorders.
Neutropenia and anemia were associated with a nonsignificant, minor positive association. Having at least one SAE
was also associated with a significant decrease in the EQ-5D-5L index score with a mean difference of -0.038 (95%
CI: -0.062 to -0.013; p = 0.002). The only SAE with >10% incidence was infections and infestations (22%).
While the association for infections and infestations and EQ-5D-5L was negative, the effect was not significant.
Discussion
HRQoL evidence is increasingly important in healthcare decision making and complements clinical and safety
outcomes in evaluating the benefit–risk balance of new oncology treatments [29–35]. Patients with DLBCL experience
a substantial burden of disease arising from both disease symptoms and treatment-related AEs, and declining
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Table 3. Mixed effects regression modelling results for adverse events and serious adverse events with incidence >10%
on the EuroQoL five-dimensions five-levels index scores.
EQ-5D-5L cohort (n = 89) Incidence Coefficient 95% CI p-value
Grade ≥3 AEs with >10% incidence in the EQ-5D-5L cohort
At least one grade ≥3 AE 78 (88%) -0.038 -0.062 to -0.013 0.002
Blood and lymphatic system disorders: 78 (88%) -0.025 -0.051–0.001 0.07
– Thrombocytopenia 57 (64%) -0.009 -0.038–0.020 0.54
– Neutropenia 45 (51%) -0.003 -0.036–0.030 0.87
– Anemia 27 (30%) 0.000 -0.039–0.039 0.99
Gastrointestinal disorders 23 (26%) -0.042 -0.090–0.006 0.09
Fatigue 13 (15%) -0.055 -0.119–0.010 0.10
Metabolism and nutrition disorders 9 (10%) -0.082 -0.120 to -0.044 0.001
Infections and infestations 20 (22%) -0.017 -0.059–0.024 0.42
SAEs with >10% incidence in the EQ-5D-5L cohort
At least one SAE 42 (47%) -0.036 -0.067 to -0.006 0.02
Infections and infestations 20 (22%) -0.021 -0.061–0.019 0.30
AE: Adverse event; EQ-5D-5L: EuroQoL five-dimensions five-levels; SAE: Serious adverse event.
HRQoL with disease progression and across increasing lines of therapy [24–27]. In one United Kingdom real-world
study, DLBCL-specific health state utility values were estimated to decrease from 0.81 (standard error = 0.016)
in first-line of therapy to 0.59 (standard error = 0.093) in third and further line of therapy as assessed with the
EQ-5D-5L [27]. Well-tolerated oral therapies could limit the potential humanistic burden associated with multidrug
injectable regimens among transplant ineligible patients with RR DLBCL.
The current analysis examined HRQoL and health utility impacts associated with oral, single-agent selinexor
in the SADAL study population of heavily pretreated patients with RR DLBCL who were not candidates for
transplantation (ASCT or CAR T-cell therapy) or experienced relapse after ASCT [23]. In the mITT population,
longitudinal mixed-effects models identified decline in HRQoL from baseline, which were significant in the early
cycles and at EOT. The clinically meaningful decline from baseline was greater than the MCID lower limit for the
FACT-G, FACT-Lym TOI and the FACT-Lym TS at all time points. Similarly, EQ-5D-5L index scores decreased
significantly from baseline to EOT, which is reflective of the heavily pretreated and advanced nature of RR DLBCL
among patients included in the analysis population.
The analysis also sought to identify HRQoL trends among treatment responders and nonresponders, given the
study population has poor prognosis and treatment should seek to delay HRQoL changes for as long as possible.
While HRQoL declined in the mITT population overall, patients who had CR or PR maintained higher HRQoL
over a longer period of time compared with patients who did not respond to treatment. Objective responders did not
experience clinically meaningful change in HRQoL from baseline during the follow-up cycles based on FACT-G,
FACT-Lym TOI or FACT-Lym TS scores according to the lower and upper limit of MCIDs. Similarly, treatment
responders had significantly higher EQ-5D-5L index scores than nonresponders by cycle 3 and experienced no
clinically meaningful change in health utility from baseline at any cycle. In contrast, nonresponders experienced
rapid, clinically meaningful HRQoL and health utility decline.
Stable disease and treatment response were associated with higher mean health utility compared with progressive
disease. The estimated difference in utility between treatment response and progressive disease was both statistically
significant and clinically meaningful as it exceeded the lower threshold of the MCID of 0.06 (mean difference: 0.07;
p = 0.001). In addition, grade ≥3 AEs and SAEs were associated with decrements in health utility, which did not
reach the lower threshold of the MCID to be assessed as clinically meaningful. Collectively, these analyses suggest
that single-agent selinexor is associated with HRQoL maintenance that is consistent with durable clinical response
and delayed disease progression in patients with objective response. In treatment responders (PR or CR), the median
OS was not reached while the median duration of response was 23 months (95% CI: 10.4–23.0) for patients with
CR and 4.4 months (95% CI: 2.0 to not estimable) for patients with PR [23]. As median progression-free survival
was 2.6 months (95% CI: 1.9–4.0), for nonresponders who experienced disease progression, duration of HRQoL
impact was short.
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Several interventional studies have examined patient-reported HRQoL and health utility in the third-line RR
DLBCL setting, including several recent reports examining CAR-T therapies [12,47,54–63]. In a recent report,
clinically meaningful improvements in HRQoL from baseline at 3, 6, 12 and 18 months were observed in
patients achieving CR or PR with tisagenlecleucel in the JULIET trial according to FACT-G, FACT-Lym TS
and FACT-Lym TOI [47]. EQ-5D-3L mapped from patient-reported Short-Form 36 data in the JULIET trial
of tisagenlecleucel corresponded to health state utility values of 0.83 for progression-free disease and 0.71 for
progressed disease [59,60]. Similarly, patients had clinically meaningful improvements at 6 and 12 months compared
with baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-
Core 30 global health, physical function, fatigue and pain scores with lisocabtagene maraleucel treatment in the
TRANSCEND NHL 001 trial [54,55]. EQ-5D-5L mean preference-weighted scores declined from baseline to
month 1 (mean difference: -0.016 [SD = 0.144]), then increased through to month 6 (mean difference: 0.019 [SD
= 0.133]) [61]. At 6 months, 30% of patients experienced improvement in health utility that exceeded an MCID
threshold of ≥0.07 [54]. In contrast to eventual improvement in HRQoL and health utility observed with CAR
T-cell therapies, HRQoL and EQ-5D-5L index scores decreased from baseline to EOT for patients in SADAL.
This trend may be reflective of baseline characteristics and prognostic factors such as age, ECOG PS and baseline
HRQoL, within the transplant-ineligible patient population of SADAL that differ from study populations of CAR
T-cell therapies.
The present study has several limitations. As SADAL was a single-arm study with no comparator arm, treatment-
associated changes in HRQoL or health utility cannot be directly tested from the clinical trial data. In addition, the
number of patients with postbaseline HRQoL data, particularly those with evaluable response, is relatively small
and decreases in later cycles. As HRQoL was an exploratory end point in SADAL, results should be interpreted
considering the study design and number of patients included in the analyses. In the responder analysis, the mixed-
effects model assumed a linear relationship between time and responder status, and that patient trajectories would
remain similar following discontinuation from the study. As patients were not randomized according to responder
and nonresponder status, comparison of HRQoL change by responder status may be confounded by differences
in unmeasured clinical characteristics which results in residual confounding. Due to the exploratory nature of the
analysis and small patient numbers, the analysis was not powered to explore the relationship between HRQoL
and disease-specific characteristics such as de novo or transformed DLBCL, genetic subtypes or prior number of
therapies. Notably in SADAL, response to selinexor was maintained across patients with de novo or transformed
DLBCL, GCB or non-GCB subtype, >2 prior systemic anti-DLBCL regimens and those who had previously
received ASCT, with overall response rates ranging from 20.6 to 38.7% [42]. While this work does not define new
insights into clinical course of the disease, it contributes to an understanding of how selinexor treatment impacts
HRQoL, which is an outcome relevant to patients, clinicians, health economists and other stakeholders. The
current analysis identified that HRQoL outcomes with selinexor were consistent with the durable clinical response
and delayed disease progression observed in patients with objective response. Additional analyses in larger patient
populations and real-world settings are warranted to further validate these findings.
Conclusion
In summary, analyses showed that patients with RR DLBCL who responded to treatment with single-agent selinexor
in the SADAL trial maintained higher HRQoL and health utilities whereas nonresponders experienced deterioration,
which was clinically meaningful. Treatment responders had higher mean health state utility compared with patients
with progressive disease and stable disease. This evidence complements the clinical benefits and manageable AE
profile of oral single-agent selinexor, which provided durable and consistent responses in heavily pretreated patients
with RR DLBCL. RR DLBCL-relevant health state utility values and disutilities derived in this study may be
applicable to future health economic evaluations.
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Summary points
• SADAL was a Phase IIb, single-arm, open-label, multicenter trial of single-agent, oral selinexor in patients with
relapsed/refractory diffuse large B-cell lymphoma (RR DLBCL) who were not eligible for transplantation and had
2–5 prior systemic therapies.
• This study examined the impact of selinexor on patient-reported health-related quality of life (HRQoL) as
assessed by the Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) and EuroQoL five-dimensions
five-levels (EQ-5D-5L) in the SADAL trial.
• Multivariable mixed-effects models were used to estimate changes in baseline in FACT – General, the FACT-Lym
Trial Outcome Index, the FACT-Lym total score and EQ-5D-5L index scores. In addition, health state utility values
and disutilities of grade ≥3 and serious adverse events (AEs) were estimated.
• The HRQoL and health utility longitudinal analyses included 101 and 89 patients, respectively, who had
completed a baseline and ≥1 postbaseline assessment and had complete baseline prognostic data.
• Patients with partial or complete response to selinexor maintained higher HRQoL than nonresponders across all
cycles of treatment, with statistically significant and clinically meaningful changes beginning in cycle 3 for FACT –
General and FACT-Lym total score (p ≤ 0.05).
• Patients with objective response (i.e., treatment responders) had a significantly higher mean EQ-5D-5L index
score than nonresponders by cycle 3, which was maintained through to cycle 7 (mean difference: 0.249 [95% CI:
0.095–0.402]; p < 0.001). Treatment responders experienced no clinically meaningful change in health utility from
baseline at any cycle.
• Estimated mean health state utility values at the end of treatment were 0.669 (95% CI: 0.619–0.719) for
progressive disease, 0.721 (95% CI: 0.658–0.784) for stable disease, and 0.739 (95% CI: 0.689–0.790) for treatment
response. The estimated difference in health state utilities between treatment response and progressive disease
was statistically significant and clinically meaningful, as it exceeded the lower threshold of the minimal clinically
meaningful differences (mean difference: 0.07; p = 0.001).
• Grade ≥3 AEs and serious AEs with incidence ≥10% in SADAL were associated with significant decrements in
EQ-5D-5L index scores (both p = 0.002). However, disutilities associated with these AEs did not reach the lower
threshold of the minimal clinically meaningful differences to be clinically meaningful.
• HRQoL maintenance in treatment responders suggests a favorable benefit–risk profile of selinexor, given its
durable response, tolerability and safety profile in patients with RR DLBCL.
• RR DLBCL-relevant health state utility values and disutilities reported in this study may be applicable to future
health economic evaluations.
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